ClinicalTrials.gg
CompletedNCT04471870ARCANGELOUpdated Sep 10, 2026

ARCANGELO (itAlian pRospective Study on CANGrELOr)

An observational study in Acute Coronary Syndrome, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 30 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Chiesi Farmaceutici S.p.A. · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,005
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 138 studies in Acute Coronary Syndrome with a site in Italy — 25 open to participants now, 29 under way, 2 of them phase 3. Acute Coronary Syndrome · Italy.

Enrollment
24th of 52
1,005 · median 1,000
Started
2020
with 3 others
Observational
53 of 138
13 open now
Registered
94th of 138
by date

Among the 138 studies in Acute Coronary Syndrome with a site in Italy, this one is the 24th largest by enrollment of the 52 observational ones that give a count, is one of 4 that started in 2020, is one of 53 observational ones, and was the 94th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

25 of the 138 studies in Acute Coronary Syndrome with a site in Italy are open now. Recruiting first, the newest first:

20 more — sign in →

All 25 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 138 studies in Acute Coronary Syndrome with a site in Italy, or all of them as a file.
02

Study summary

The Sponsor implemented a post-authorisation safety study (PASS), category 3, focused in Acute Coronary Syndrome, in order to collect information about the safety of cangrelor in the real clinical practice, evaluating the safety of the transition to all the oral P2Y12 inhibitors (cangrelor, ticagrelor and prasugrel).

03

Conditions studied

  • Acute Coronary Syndrome

Keywords

  • Real-word
  • ACS
  • PCI
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients with acute coronary syndromes undergoing percutaneous coronary intervention who receive cangrelor i.v. according to the clinical practice

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients' written informed and privacy consent obtained before or at the end of the PCI procedure according to patients' condition but in any case, prior to collection of any study-related data;
  2. Male or female patients aged ≥ 18 years;
  3. Patients with acute coronary syndromes undergoing PCI;
  4. Patients who are planned to be treated with cangrelor, or who have received treatment with cangrelor.

Exclusion criteria

Exclusion Criteria:

  1. Patients with active bleeding or increased risk of bleeding, because of impaired haemostasis and/or irreversible coagulation disorders or due to recent major surgery/trauma or uncontrolled severe hypertension;
  2. Patients with history of stroke or (TIA);
  3. Patients with to the active substance (cangrelor) or to any of its ;
  4. Known pregnancy or breast-feeding female patients;
  5. Patients with stable angina (SA).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,005 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Incidence of any haemorrages according to BARC (Bleeding Academic Research Consortium) criteria

    The incidence will be calculated as the ratio between the number of patients experiencing at least one event during the 30-day observation period over the total number of evaluable patients.

    Time frame: 30 days post-PCI

Secondary outcomes

  1. Incidence of type 1-2 (mild) bleedings, according to the Bleeding Academic Research Consortium [BARC] criteria

    The incidence will be calculated as the ratio between the number of evaluable patients who experience at least one event and the total number of evaluable patients

    Time frame: 48 hours after PCI

  2. Incidence of type 1-2 (mild) bleedings, according to the Bleeding Academic Research Consortium [BARC] criteria

    The incidence will be calculated as the ratio between the number of evaluable patients who experience at least one event and the total number of evaluable patientsConsortium \[BARC\]

    Time frame: 30 days after PCI

  3. Incidence of type 3-5 (moderate severe) bleedings, according to the Bleeding Academic Research Consortium [BARC] criteria

    The incidence will be calculated as the ratio between the number of evaluable patients who experience at least one event and the total number of evaluable patientsConsortium \[BARC\]

    Time frame: 48 hours after PCI

  4. Incidence of type 3-5 (moderate severe) bleedings, according to the Bleeding Academic Research Consortium [BARC] criteria

    The incidence will be calculated as the ratio between the number of evaluable patients who experience at least one event and the total number of evaluable patientsConsortium \[BARC\] bleedings, according to the Bleeding Academic Research Consortium \[BARC\]

    Time frame: 30 days after PCI

  5. Incidence of major adverse cardiac events (MACE)

    The incidence will be calculated as the ratio between the number of evaluable patients who experience at least one event and the total number of evaluable patients. MACE will comprise any of the following events: death, myocardial infarction (MI), ischemia-driven revascularisation (IDR) and stent thrombosis (ST).

    Time frame: 48 hours after PCI

  6. Incidence of major adverse cardiac events (MACE)

    The incidence will be calculated as the ratio between the number of evaluable patients who experience at least one event and the total number of evaluable patients. MACE will comprise any of the following events: death, myocardial infarction (MI), ischemia-driven revascularisation (IDR) and stent thrombosis (ST).

    Time frame: 30 days after PCI

  7. To describe the type of oral platelet P2Y12 receptor (prasugrel/ticagrelor/clopidogrel)

    It will be calculated the proportion of patients receiving an oral platelet P2Y12 receptor in terms of type (prasugrel/ticagrelor/clopidogrel) and timing of administration

    Time frame: 30 days after PCI

  8. To describe the use of glycoprotein IIb/IIIa (GPIIb/IIIa) inhibitors

    It will be calculated the proportion of patients receiving GPIIb/IIIa inhibitors

    Time frame: 30 days after PCI

07

Study locations

30 sites
  • A.O.U. Riuniti
    Ancona, Italy
  • Ospedale San Donato
    Arezzo, Italy
  • A.O.U. Consorziale Policlinico
    Bari, Italy
  • Ospedale San Bassiano
    Bassano del Grappa, Italy
  • Azienda Ospedaliera San Pio
    Benevento, Italy
  • Ospedale Maggiore
    Bologna, Italy
  • Fondazione Poliambulanza
    Brescia, Italy
  • A.O. Sant'Anna e San Sebastiano
    Caserta, Italy
  • A.O.U. Policlinico-Vittorio Emanuele P.O. Ferrarotto
    Catania, Italy
  • Ospedale SS Annunziata
    Cosenza, Italy
  • ASO Santa Croce e Carle
    Cuneo, Italy
  • A.O.U. Careggi
    Florence, Italy
  • Ospedale Fabrizio Spaziani
    Frosinone, Italy
  • Ospedale S. Andrea
    La Spezia, Italy
  • Ospedale Santa Maria Goretti
    Latina, Italy
  • Fondazione Toscana "G. Monasterio" Ospedale del Cuore G. Pasquinucci
    Massa, Italy
  • Centro Cardiologico Monzino
    Milan, Italy
  • A.O.R.N. A. Cardarelli
    Naples, Italy
  • A.O.U. Federico II
    Naples, Italy
  • A.O. Padova
    Padova, Italy
  • Policlinico San Matteo
    Pavia, Italy
  • Ospedale degli Infermi
    Rivoli, Italy
  • San Camillo Forlanini
    Roma, 00152, Italy
  • Aurelia Hospital
    Roma, Italy
  • Fondazione Policlinico Universitario A. Gemelli
    Roma, Italy
  • A.O.U. Sassari
    Sassari, Italy
  • Ospedale Umberto I
    Syracuse, Italy
  • A.O. Mauriziano
    Torino, Italy
  • Ospedale Santa Chiara
    Trento, Italy
  • Ospedale Ca' Foncello
    Treviso, Italy
08

References and documents

Publications

  • De Luca L, Calabro P, Chirillo F, Rolfo C, Menozzi A, Capranzano P, Menichelli M, Nicolini E, Mauro C, Trani C, Versaci F, Tomai F, Musumeci G, Di Mario C, Pepe M, Berti S, Cernetti C, Cirillo P, Maffeo D, Talanas G, Ferlini M, Contarini M, Lanzilotti V, Scherillo M, Tarantini G, Muraglia S, Rossini R, Bolognese L; ARCANGELO study group. Use of cangrelor in patients with acute coronary syndromes undergoing percutaneous coronary intervention: Study design and interim analysis of the ARCANGELO study. Clin Cardiol. 2022 Sep;45(9):913-920. doi: 10.1002/clc.23878. Epub 2022 Jun 22. PubMed 35733352 ↗
  • Capranzano P, Calabro P, Musumeci G, Di Mario C, Nicolini E, Mauro C, Trani C, Versaci F, Tomai F, Pepe M, Berti S, Cernetti C, Cirillo P, De Luca L. Use of cangrelor in patients with reduced renal function: Post-hoc analysis from the ARCANGELO study. Int J Cardiol. 2026 Oct 1;460:134601. doi: 10.1016/j.ijcard.2026.134601. Epub 2026 Jun 3. PubMed 42242385 ↗
  • Capranzano P, Calabro P, Musumeci G, Mario CD, Chirillo F, Rolfo C, Menozzi A, Menichelli M, Maffeo D, Talanas G, Ferlini M, Contarini M, Lanzilotti V, De Luca L. Use of Cangrelor in Older Patients: Findings from the itAlian pRospective Study on CANGrELOr Study. Am J Cardiol. 2025 Apr 1;240:31-37. doi: 10.1016/j.amjcard.2024.12.021. Epub 2024 Dec 21. PubMed 39716523 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2020 to primary completion in Jan 2022, 14 months.

Of 34 industry-sponsored observational studies under Acute Coronary Syndrome, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 42. This study's 14 months is below that.

Counting every sponsor, half of 277 studies reached it within 35 months; a quarter within 18 and three quarters within 68.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 6, 2020
First posted
Jul 15, 2020
StartActual
Oct 23, 2020
Primary completionActual
Jan 17, 2022
CompletionActual
Jan 17, 2022
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04471870
Responsible party
Sponsor
First posted
Jul 15, 2020
Start date
Oct 23, 2020
Primary completion
Jan 17, 2022
Completion
Jan 17, 2022
Last update
Sep 10, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion